|Boston papers have enough interesting biotech companies in their own back yard, why send someone down here? |
You should have been around when I was giving Oscient the same "show us your critical signs of progress" critique on Yahoo. I think they are still in BK court.
Rib-X looks interesting, but seems to have stalled recently.... and of course you have Cubist which is a true success story, and example of how smart people can capitalize on a big pharma (Lilly) missed opportunity...nice price action in the past few months.
With the recent Pfizer announcement that they are licensing one of their bigger pipeline libraries to the Harvard system for development, I suspect there will be many more spin-out companies in Boston soon enough to keep your friend busy.